Global health experts and medical researchers have renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) [1].
The change aims to shift the medical focus from the presence of ovarian cysts to the systemic hormonal and metabolic disruptions that characterize the condition. By updating the terminology, researchers hope to improve diagnostic accuracy and reduce the stigma associated with the disorder [2].
Medical data indicates the condition is widespread, affecting approximately one in eight women worldwide [3]. The previous name, Polycystic Ovary Syndrome, primarily highlighted the ovaries, which often misled patients and providers into believing the condition was limited to the reproductive system.
The new designation, Polyendocrine Metabolic Ovarian Syndrome, explicitly acknowledges the role of the endocrine system and metabolic health [4]. Experts said the broader name reflects the complex nature of the syndrome, which involves insulin resistance and hormonal imbalances that affect the entire body, not just the ovaries.
While most reports identify the new abbreviation as PMOS [1], some sources have referred to the change as a shift to PMO [5]. Despite the variation in abbreviation, the intent remains the same: to align the name with the biological reality of the disease [2].
This transition is expected to assist clinicians in identifying the syndrome earlier in patients who may not present with cysts but exhibit other metabolic symptoms [4]. By broadening the clinical definition, the medical community intends to ensure more women receive appropriate treatment for the systemic effects of the syndrome [2].
“Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS)”
The renaming of PCOS to PMOS represents a fundamental shift in how the medical community views the disorder, moving it from a localized gynecological issue to a systemic metabolic condition. This change is likely to lead to more comprehensive screening processes that prioritize endocrine health and insulin levels over simple ultrasound findings of ovarian cysts, potentially increasing the rate of early diagnosis for women who do not meet the traditional 'polycystic' criteria.
